Dmoszyñska A, Kleinrok A, Dabrowski P, Sokoluk I, Markiewicz M, Ledwozyw A, Sokołowska B
Kliniki Hematologii AM, Lublinie.
Pol Arch Med Wewn. 1992 Nov;88(5):287-94.
18 patients were studied with primary hypercholesterolemia (type II according to Fredricksen) and fasting cholesterol level during low fat diet above 250 mg/dl. Blood samples were taken: I--before lovastatin administration on diet, II--after 4 weeks administration of 20 mg, III--after 4 weeks of 80 mg and IV--4 weeks after the drug discontinued. The following tests were performed: platelets aggregation induced by ADP and adrenaline, PF3 and PF4, platelet MDA, serum triglycerides, total cholesterol, HDL-cholesterol and LDL-cholesterol. Before treatment patients showed significant platelets hyperaggregation and MDA concentration comparing to the control group. During the drug administration significant lowering of platelets MDA concentration, was observed small but significant HDL cholesterol level increase which correlated with platelet MDA concentration. Availability of PF3 and release of PF4 did not change during study.
对18例原发性高胆固醇血症患者（根据弗雷德里克森分类为II型）进行了研究，这些患者在低脂饮食期间的空腹胆固醇水平高于250mg/dl。采集血样：I——在饮食基础上服用洛伐他汀之前；II——服用20mg洛伐他汀4周后；III——服用80mg洛伐他汀4周后；IV——停药4周后。进行了以下检测：由ADP和肾上腺素诱导的血小板聚集、PF3和PF4、血小板丙二醛、血清甘油三酯、总胆固醇、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇。治疗前，与对照组相比，患者表现出显著的血小板高聚集和丙二醛浓度升高。在药物治疗期间，观察到血小板丙二醛浓度显著降低，高密度脂蛋白胆固醇水平有小幅但显著的升高，且与血小板丙二醛浓度相关。在研究期间，PF3的可用性和PF4的释放没有变化。
